Digestive Diseases and Sciences

, Volume 53, Issue 12, pp 3128–3132 | Cite as

A Glass of Water Immediately Increases Gastric pH in Healthy Subjects

  • George Karamanolis
  • Ioanna Theofanidou
  • Marina Yiasemidou
  • Evangelos Giannoulis
  • Konstantinos Triantafyllou
  • Spiros D. Ladas
Original Paper


Onset of action of antisecretory agents is of pivotal importance for patients with gastroesophageal reflux disease (GERD) treated “on-demand.” Aim To study the acute effect of acid-inhibiting drugs and water administration on gastric pH. Method A cross-over study was performed in 12 H. pylori (-), healthy subjects (6 men; mean age: 26 years). A single oral dose of the following agents was received with a wash-out period between each study: a glass of water (200 ml), antacid, ranitidine, omeprazole, esomeprazole, and rabeprazole. Gastric pH was recorded for 6 h after drug intake. Results Water increased gastric pH >4 in 10/12 subjects after 1 min. The time (median) needed to pH >4 was for: antacid 2 min, ranitidine 50 min, omeprazole 171 min, esomeprazole 151 min, and rabeprazole 175 min. Gastric pH >4 lasted for 3 min after water and for 12 min after antacids; it remained >4 until the end of recording in: 4/12 subjects with ranitidine, 11/12 with rabeprazole, and all with omeprazole and esomeprazole. Conclusion Water and antacid immediately increased gastric pH, while PPIs showed a delayed but prolonged effect compared to ranitidine.


Water antacids PPIs Ranitidine Gastric pH Onset of action 


  1. 1.
    Kennedy T, Jones R (2000) The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 14:1589–1589. doi: 10.1046/j.1365-2036.2000.00884.x PubMedCrossRefGoogle Scholar
  2. 2.
    Jacobson BC, Ferris TG, Shea TL et al (2003) Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98:51–58. doi: 10.1111/j.1572-0241.2003.07186.x PubMedCrossRefGoogle Scholar
  3. 3.
    Fass R, Fennerty MB, Vakil N (2001) Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol 96:303–314PubMedGoogle Scholar
  4. 4.
    Carlson R, Dent J et al (1998) Gastro-esophageal reflux disease (GORD) in primary care- an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 10:119–124. doi: 10.1097/00042737-199802000-00004 CrossRefGoogle Scholar
  5. 5.
    Tytgat GNJ, Blum AL, Verlinden M (1995) Prognostic factors for relapse and maintenance treatment with cisapride in gastro-esophageal reflux disease. Aliment Pharmacol Ther 9:271–280PubMedGoogle Scholar
  6. 6.
    Goh KL (2006) “On-demand” therapy for gastroesophageal reflux disease: are current proton pump inhibitors good candidates? J Gastroentrol Hepatol 21(Suppl 5):S115–S118. doi: 10.1111/j.1440-1746.2006.04714.x CrossRefGoogle Scholar
  7. 7.
    Hatlebakk JG, Berstad A (1996) Pharmacokinetic optimization in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 31:386–406PubMedGoogle Scholar
  8. 8.
    Bell NJ, Burget D, Howden CW et al (1992) Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59–67PubMedCrossRefGoogle Scholar
  9. 9.
    Hurlimann S, Abbuhl B, Inauen W et al (1994) Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 8:193–201PubMedCrossRefGoogle Scholar
  10. 10.
    Arnestad JS, Klevemand PM, Waldum HL (1997) In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment Pharmacol Ther 11:355–358. doi: 10.1046/j.1365-2036.1997.300000.x PubMedCrossRefGoogle Scholar
  11. 11.
    Inamori M, Towaga JI, Iwasaki T et al (2005) Early effects of lafutidine or rabeprazole on intragastric acididty: which drug is more suitable for on-demand use? J Gastroenterol 40:453–458. doi: 10.1007/s00535-005-1569-0 PubMedCrossRefGoogle Scholar
  12. 12.
    Khoury RM, Katz PO, Castell DO (1999) Post-pradial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy subjects. Aliment Pharmacol Ther 1211–1214. doi: 10.1046/j.1365-2036.1999.00587.x
  13. 13.
    Robinson M (2001) New generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 13(Suppl 1):S43–S47PubMedGoogle Scholar
  14. 14.
    Hedenstrom H, Alm C, Kraft M, Grahnen A (1997) Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 11:1137–1141. doi: 10.1046/j.1365-2036.1997.00264.x PubMedCrossRefGoogle Scholar
  15. 15.
    Chassany O, Bergmann JF, Simoneau G et al (1996) The comparative effects of single intravenous doses of cimetidine, ranitidine, famotidine, and omeprazole on intragastric pH. Curr Ther Res 57:159–169. doi: 10.1016/S0011-393X(96)80121-4 CrossRefGoogle Scholar
  16. 16.
    Abe Y, Inamori M, Togawa J et al (2004) The comperative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol 39:21–25. doi: 10.1007/s00535-003-1286-5 PubMedCrossRefGoogle Scholar
  17. 17.
    Pantoflickova D, Dorta G, Ravic M et al (2003) Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 17:1507–1514. doi: 10.1046/j.1365-2036.2003.01496.x PubMedCrossRefGoogle Scholar
  18. 18.
    Zacny J, Zamakhshary M, Skertis I, Veldhuyzen van Zanten S (2005) Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 21:1299–1312. doi: 10.1111/j.1365-2036.2005.02490.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • George Karamanolis
    • 1
  • Ioanna Theofanidou
    • 1
  • Marina Yiasemidou
    • 1
  • Evangelos Giannoulis
    • 1
  • Konstantinos Triantafyllou
    • 1
  • Spiros D. Ladas
    • 2
  1. 1.Hepatogastroenteroly Unit, 2nd Department of Internal Medicine-Propaedeutic, “Attikon” University General HospitalAthens UniversityAthensGreece
  2. 2.Hepatogastroenteroly Unit, First Department of Internal Medicine-Propaedeutic, “Laikon” General HospitalAthens UniversityAthensGreece

Personalised recommendations